Liquidia CorpLQDAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Liquidia Corp is a late-stage biopharmaceutical firm focused on developing and commercializing innovative inhaled therapies for respiratory and rare diseases. It uses its proprietary PRINT particle engineering tech to create optimized drug products, with core markets in North America covering pulmonary arterial hypertension and asthma indications.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Caligan Partners LP | 9.60% | 8.1M | ▲ +0.50pp | 2024-09-12 |
| Legend Aggregator, LP | 9.50% | 7.2M | — | 2024-01-16 |
| OF ABOVE PERSONS | 7.90% | 6.7M | ▼ -1.30pp | 2024-11-12 |
| BlackRock, Inc. | 5.00% | 4.2M | flat | 2024-11-08 |
Insider Transactions
Net 90d: −$29.62M · buys $0 / sells $29.62MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-27 | Jason Adair | Chief Business Officer | Sell (open market) | 688 | $41.65 | $28.7K |
| 2026-04-27 | Dana Boyle | Chief Accounting Officer | Sell (open market) | 1.6K | $37.78 | $59.5K |
| 2026-04-17 | JEFFS ROGER | Chief Executive Officer | Sell (open market) | 18.8K | $40.60 | $765.0K |
| 2026-04-16 | JEFFS ROGER | Chief Executive Officer | Sell (open market) | 25.0K | $40.31 | $1.01M |
| 2026-04-15 | Michael Kaseta | CFO and COO | Sell (open market) | 9.0K | $40.14 | $363.0K |
| 2026-04-15 | Michael Kaseta | CFO and COO | Option exercise | 87.0K | $2.79 | $242.6K |
| 2026-04-15 | Michael Kaseta | CFO and COO | Sell (open market) | 87.0K | $40.14 | $3.49M |
| 2026-04-15 | Michael Kaseta | CFO and COO | Sell (open market) | 43.4K | $40.14 | $1.74M |
| 2026-04-15 | JEFFS ROGER | Chief Executive Officer | Sell (open market) | 25.0K | $40.14 | $1.00M |
| 2026-04-14 | Michael Kaseta | CFO and COO | Option exercise | 3.0K | $2.79 | $8.4K |
1–10 of 71
Page 1 / 8